Carlsmed, Inc. (CARL)
| Market Cap | 387.63M |
| Revenue (ttm) | 50.51M |
| Net Income (ttm) | -30.22M |
| Shares Out | 26.60M |
| EPS (ttm) | -2.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 248,321 |
| Open | 14.34 |
| Previous Close | 14.56 |
| Day's Range | 14.04 - 15.19 |
| 52-Week Range | 10.65 - 17.19 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.25 (+38.98%) |
| Earnings Date | Feb 25, 2026 |
About CARL
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California. [Read more]
Financial Performance
In 2025, Carlsmed's revenue was $50.51 million, an increase of 85.94% compared to the previous year's $27.17 million. Losses were -$30.22 million, 21.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CARL stock is "Strong Buy." The 12-month stock price target is $20.25, which is an increase of 38.98% from the latest price.
News
Carlsmed, Inc. (CARL) Q4 2025 Earnings Call Transcript
Carlsmed, Inc. (CARL) Q4 2025 Earnings Call Transcript
Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsme...
Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference
CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 ...
Carlsmed Announces first corra™ personalized Cervical Plating Procedure
The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfoli...
Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will repo...
Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure
CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery u...
Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024
Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal
CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Jou...
Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference
CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting a...
Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop First 50+ cervical cases completed; observations o...
Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference
CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting ...
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, ...
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will repo...
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary
CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solution...
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index
CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solution...
UPDATE - Carlsmed® Reports Second Quarter 2025 Financial Results
Q2'25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Compa...
Carlsmed® Reports Second Quarter 2025 Financial Results
Q2'25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Compa...
Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025
CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will repo...
Carlsmed's aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures
CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Ho...
Carlsmed's aprevo® Powers First Personalized Cervical Spine Surgery
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced...
Carlsmed: Spine Play Does Not Have My Backing Yet
Carlsmed's IPO debut is steady, with shares trading near the offering price, reflecting investor caution on its one-product, loss-making business model. Despite doubling sales and manageable cash burn...
Carlsmed Announces Pricing of Initial Public Offering
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the pricing of...
Carlsmed Announces Launch of Initial Public Offering
CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the launch of ...
U.S. IPO Weekly Recap: Mining Companies Lead The Calendar As More Sizable IPOs Submit Initial Filings
Six issuers debuted in the US this past week, led by two mining companies. Three blank check companies also went public, and a handful of notable IPO candidates joined the pipeline. Four sizable IPOs ...
Carlsmed Files For IPO On High Growth And High Operating Losses
Carlsmed, Inc. has filed to raise $100 million in a U.S. IPO, but the final figure may differ. The company targets a large, but moderately growing spinal surgery market, with expansion plans in cervic...